Shareholders Foundation, Inc.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Long-Term Investor Alert: Investigation over Potential Wrongdoing

An investigation on behalf of investors of NASDAQ:VRTX shares over potential breaches of fiduciary duties by certain officers and directors of Vertex Pharmaceuticals Incorporated was announced and NASDAQ:VRTX investors should contact the Shareholders Foundation.

 

San Diego, CA -- (SBWIRE) -- 06/26/2012 -- Certain officer and directors of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) are under investigation over possible breaches of fiduciary duties in connection with certain financial statements.

Investors who are current long-term stockholders in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) concerning whether the company, certain of its officers and directors, or others have possibly violated federal securities laws. Specifically, the investigation concerns whether certain statements about Vertex Pharmaceuticals’ business, its prospects and its operations were potentially materially false and misleading at the time they were made.

On May 7, 2012, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that the Interim Data from the Phase 2 Combination Study of its VX-809 and KALYDECO™ (ivacaftor) showed significant improvements in Lung Function (FEV1) in people with cystic fibrosis who have two copies of the F508del mutation.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) jumped from $37.41 per share on May 7, 2012, to $64.16 per share on May 8, 2012.

However, on May 29, 2012, before the market opened, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that it corrected and provided additional data from the recent interim analysis of Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) in people with cystic fibrosis who have two copies of the F508del mutation.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) dropped from $64.85 on May 25, 2012 to $50.51 per share on May 29, 2012.

On June 25, 2012, NASDAQ:VRTX shares closed at $58.43 per share.

Those who are current long term stockholders in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Joelle Day
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com